XBiotech halts all rheumatology research after missing Phase II endpoints
XBiotech’s stock price has taken a hit after it announced a complete halt to its clinical program in rheumatological diseases…
News
Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial
Zura Bio initiates Phase II systemic sclerosis treatment trial
First patient dosed as Marengo’s invikafusp alfa trial expands to Europe
BMS sees success in Phase III Sotyktu psoriatic arthritis trials
JCR Pharmaceuticals doses first patient in paediatric growth hormone trial
GSK’s combo therapy trial for advanced ovarian cancer meets primary endpoint
First blood-stage malaria vaccine ‘a much-needed addition’ – analyst
